Drug Profile


Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Peptides
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 26 Jul 2016 Preclinical trials in Paroxysmal nocturnal haemoglobinuria in Australia (SC)
  • 26 Jul 2016 Apellis Pharmaceuticals plans a phase I trial In volunteers in Australia (ACTRN12616000862448p )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top